Evidence map›Paper›PMID 31963760›Full record

ReviewInternational journal of molecular sciences2020

Multiple Cell Signalling Pathways of Human Proinsulin C-Peptide in Vasculopathy Protection.

Selma B Souto, Joana R Campos, Joana F Fangueiro, Amélia M Silva, Nicola Cicero, Massimo Lucarini, Alessandra Durazzo, Antonello Santini, Eliana B Souto

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Neural Stem Cell-based Regenerative Therapy: A New Approach to Diabetes Treatment.Endocrine, metabolic & immune disorders drug targets · 2024
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Plants and Diabetes: Description, Role, Comprehension and Exploitation.International journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Selma B SoutoDepartment of Endocrinology, Hospital de São João, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
Joana R CamposDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, 3000-548 Coimbra, Portugal.
Joana F FangueiroDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, 3000-548 Coimbra, Portugal.
Amélia M SilvaDepartment of Biology and Environment, University of Trás-os-Montes e Alto Douro, UTAD, Quinta de Prados, P-5001-801 Vila Real, Portugal.
Nicola CiceroDipartimento di Scienze biomediche, odontoiatriche e delle immagini morfologiche e funzionali, Università degli Studi di Messina, Polo Universitario Annunziata, 98168 Messina, Italy.
Massimo LucariniCREA-Research Centre for Food and Nutrition, Via Ardeatina 546, 00178 Rome, Italy.
Alessandra DurazzoCREA-Research Centre for Food and Nutrition, Via Ardeatina 546, 00178 Rome, Italy.
Antonello SantiniDepartment of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Napoli, Italy.
Eliana B SoutoDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, 3000-548 Coimbra, Portugal.
University of Coimbra · PTHospital de São João · PTUniversity of Messina · ITUniversity of Naples Federico II · ITUniversity of Trás-os-Montes and Alto Douro · PT

Funding

: Nutraceutica come supporto nutrizionale nel paziente oncologico, CUP: B83D18000140007Portuguese Science and Technology Foundation (FCT/MCT) and European Funds (PRODER/COMPETE) M-ERA-NET/0004/2015-PAIRED and UID/QUI/50006/2013, co-financed by FEDER, under the Partnership Agreement PT2020
6 · The paper itself

Abstract

A major hallmark of diabetes is a constant high blood glucose level (hyperglycaemia), resulting in endothelial dysfunction. Transient or prolonged hyperglycemia can cause diabetic vasculopathy, a secondary systemic damage. C-Peptide is a product of cleavage of proinsulin by a serine protease that occurs within the pancreatic β-cells, being secreted in similar amounts as insulin. The biological activity of human C-peptide is instrumental in the prevention of diabetic neuropathy, nephropathy and other vascular complications. The main feature of type 1 diabetes mellitus is the lack of insulin and of C-peptide, but the progressive β-cell loss is also observed in later stage of type 2 diabetes mellitus. C-peptide has multifaceted effects in animals and diabetic patients due to the activation of multiple cell signalling pathways, highlighting p38 mitogen-activated protein kinase and extracellular signal-regulated kinase ½, Akt, as well as endothelial nitric oxide production. Recent works highlight the role of C-peptide in the prevention and amelioration of diabetes and also in organ-specific complications. Benefits of C-peptide in microangiopathy and vasculopathy have been shown through conservation of vascular function, and also in the prevention of endothelial cell death, microvascular permeability, neointima formation, and in vascular inflammation. Improvement of microvascular blood flow by replacing a physiological amount of C-peptide, in several tissues of diabetic animals and humans, mainly in nerve tissue, myocardium, skeletal muscle, and kidney has been described. A review of the multiple cell signalling pathways of human proinsulin C-peptide in vasculopathy protection is proposed, where the approaches to move beyond the state of the art in the development of innovative and effective therapeutic options of diabetic neuropathy and nephropathy are discussed.

Indexed as

C-PeptideHumansMAP Kinase Signaling SystemNitric OxideVascular DiseasesC-PeptideNitric OxideC-peptidediabetes mellitusdiabetic nephropathydiabetic neuropathyvasculopathy

Identifiers

PMID31963760
PMCPMC7013900
OpenAlexW3000732953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.